Elicio Therapeutics, Inc ELTX 深 滬
已收盤 02-06 16:00:00 美东时间
8.32
+0.710
+9.33%
華盛通- 最 高8.34
- 今 開7.75
- 成交量 11.58万股
- 最 低 7.505
- 昨 收 7.61
- 總市值 1.46亿
- 52周最高 12.62
- 市盈率 靜 --
- 換手率 0.66%
- 52周最低 4.60
- 委 比 -89.56%
- 總股本 1748.95万
- 歷史最高 263.00
- 量 比 0.63
- 振 幅 10.97%
- 歷史最低 2.96
- 每 手 1
- 風險率 1.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Elicio Therapeutics Announces That Analysis Of Subset Of Patients In Ongoing Phase 2 AMPLIFY-7P Trial Shows That Majority Of Evaluated Patients Treated With ELI-002 7P Induced Antigen Spreading Targeting Non-mKRAS Neoantigens That Are Not Present In ELI-002 7P Targeted Immunotherapy
Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunotherapy87% (13/15) of
2025-12-11 21:04
Elicio Announces Additional Immunogenicity Data From Ongoing Phase 2 AMPLIFY-7P Trial Evaluating ELI-002 7P In Patients With mKRAS PDAC And New Preclinical Data On Immunotherapy Candidate ELI-004, For Treatment Of Solid Tumors
SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapyELI-002 7P induced
2025-11-07 22:10
Elicio Therapeutics Announced That Preliminary Analysis Of Patients In The Ongoing Phase 2 AMPLIFY-7P Trial Indicated That Specific Human Leukocyte Antigen Types; ELI-002 7P Shows Broad T-Cell Response Against mKRAS-Mutated Cancers Across Diverse Patient HLA Types
ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use among a diverse patient populationPatients treated with ELI-002 7P represented a
2025-10-27 20:22
Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial
Elicio Therapeutics announced preliminary results from its Phase 2 AMPLIFY-7P trial showing ELI-002 7P induced robust mKRAS-specific T cell responses across a diverse HLA population. Among 89 patients, 1,132 unique HLA types were identified, with 99% of patients (88/89) developing mKRAS-specific T cell responses. These findings suggest ELI-002 7P may benefit a broad spectrum of pancreatic ductal adenocarcinoma (PDAC) patients, addressing a critic...
2025-10-27 12:00
Elicio Therapeutics Announces Planned Initiation Of Investigator-Initiated Phase 1 Trial Of ELI-002 7P In Combination With Chemotherapy And Anti-PD1 Checkpoint Inhibitor In Borderline And Resectable PDAC
Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor ("CPI") in the neoadjuvant setting Trial is anticipated to begin enrolling in H1'2026 BOSTON, Sept. 29, 2025 (GLOBE
2025-09-29 20:19
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
Elicio Therapeutics plans to initiate a Phase 1 neoadjuvant study of ELI-002 7P, an investigational AMP cancer vaccine targeting KRAS-driven cancers, in combination with chemotherapy (mFOLFIRINOX) and an anti-PD-1 checkpoint inhibitor for pancreatic ductal adenocarcinoma (PDAC). The investigator-initiated trial, led by Dr. Kevin Soares of Memorial Sloan Kettering Cancer Center and funded by the Lustgarten Foundation, aims to enroll 20 patients ac...
2025-09-29 12:00
Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics granted 9,800 inducement stock options to two new employees on September 15, 2025, priced at $10.08 per share, vesting over four years. The company, focusing on novel immunotherapies for high-prevalence cancers, is advancing its lead program ELI-002, an off-the-shelf vaccine targeting KRAS mutations, with promising data from Phase 1 studies in pancreatic and colorectal cancers. Elicio plans to expand ELI-002 to other indicatio...
2025-09-18 12:00
Elicio's ELI-002 Triggers mKRAS-Specific T Cell Responses In 99% Of Phase 2 AMPLIFY-7P Trial Patients
ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine immunotherapyRobust mKRAS-specific T cell responses were observed with an average
2025-09-17 20:08
美股牛股 | 迅雷绩后上演翻倍行情！投资影石创新浮盈超50亿；OpenDoor隔夜大涨19%
迅雷绩后上演翻倍行情！投资影石创新浮盈超50亿；OpenDoor隔夜大涨19%，此前获知名加密货币投资者买入>>
2025-08-19 19:53
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
Elicio Therapeutics reported promising results from the Phase 1 AMPLIFY-201 study of ELI-002, a mutant KRAS (mKRAS)-targeting vaccine, in patients with pancreatic and colorectal cancers. The study showed a significant improvement in overall survival (OS) from 16.33 to 28.94 months, alongside a 77% reduction in the risk of death and an 88% reduction in the risk of relapse. ELI-002 induced robust T cell responses, particularly CD4+ and CD8+ mKRAS-s...
2025-08-12 12:00
